325 related articles for article (PubMed ID: 29141648)
1. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
4. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.
Kim KI; Huh IS; Kim IW; Park T; Ahn KS; Yoon SS; Yoon JH; Oh JM
Eur J Cancer; 2013 Jan; 49(2):403-10. PubMed ID: 22964418
[TBL] [Abstract][Full Text] [Related]
5. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
[TBL] [Abstract][Full Text] [Related]
6. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
7. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
Wan H; Zhu J; Chen F; Xiao F; Huang H; Han X; Zhong L; Zhong H; Xu L; Ni B; Zhong J
J Exp Clin Cancer Res; 2014 Nov; 33(1):90. PubMed ID: 25398670
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
9. STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
Xu P; Zhou D; Ouyang J; Chen B
Leuk Lymphoma; 2016; 57(4):921-6. PubMed ID: 26384082
[TBL] [Abstract][Full Text] [Related]
10. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
11. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.
Xiao Q; Deng D; Li H; Ye F; Huang L; Zhang B; Ye B; Mo Z; Yang X; Liu Z
Ann Hematol; 2014 Aug; 93(8):1381-90. PubMed ID: 24994605
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
13. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
14. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
[TBL] [Abstract][Full Text] [Related]
15. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
[TBL] [Abstract][Full Text] [Related]
16. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
[TBL] [Abstract][Full Text] [Related]
17. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
Chen P; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Chen XP
J Transl Med; 2018 Jul; 16(1):197. PubMed ID: 30016963
[TBL] [Abstract][Full Text] [Related]
18. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.
Yuan XQ; Zhang DY; Yan H; Yang YL; Zhu KW; Chen YH; Li X; Yin JY; Li XL; Zeng H; Chen XP
Oncotarget; 2016 Sep; 7(37):60555-60574. PubMed ID: 27528035
[TBL] [Abstract][Full Text] [Related]
20. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
